ICU Management & Practice, Volume 21 - Issue 1, 2021

How Should We Manage Sedation in Critically-Ill COVID-19 Patients?

share Share

Clinical Practice Guidelines

The Choosing Wisely top five guidelines published a few years ago by the Chest Association of Physicians, the American Thoracic Society, the Society of Critical Care Medicine, and the American Association of Critical Care Nurses state that mechanically ventilated patients should not be deeply sedated without a specific indication and without daily attempts to lighten sedation (Halpern et al. 2014).


This is a very important recommendation, especially when discussing sedation in critically-ill COVID-19 patients.Findings from a landmark study published by the Chicago Study Group 20 years ago showed that if daily sedation is interrupted in mechanically ventilated patients, the duration of mechanical ventilation can be shortened (Kress et al. 2000).


Pain

The most recently published guidelines from 2018 recommend a checklist. The first step is to make sure that mechanically ventilated patients are not in pain. Pain should be measured using appropriate scales, and pain management should be initiated with intravenous opioid drugs but also non-opioid analgesics to spare the excessive use of opiates. The most commonly used scale is the Behavioral Pain Scale (BPS) that ranges from 3 to 12, 3 representing a patient with no pain at all and 12 being a patient experiencing very intense pain.




Sedation

The next step, once the pain is treated, is sedation. The 2018 guidelines suggest that light sedation and not deep sedation should be used in critically-ill mechanically ventilated adults. Light sedation is associated with a shorter duration of invasive mechanical ventilation and reduced tracheotomy rates (Devlin et al. 2018).


In a multi-centre study, authors showed that most of the patients were deeply sedated in their first 48 hours of the ICU stay. However, this proportion decreased with time. In this study, deep sedation was associated with a longer time to extubation and a lower survival rate. Deep sedation was also associated with a higher mortality rate three months after the ICU stay (Shehabi et al. 2012).


Light sedation can be defined using scales. One of the most used scales is the Richmond Agitation and Sedation Scale, known as the RASS scale. Light sedation is between -2 to +1. Light sedation and sometimes even no sedation can be performed in many mechanically ventilated patients.


In a randomised trial published in 2020 in the New England Journal of Medicine, the authors showed that no sedation or light sedation could be performed in many patients admitted to the ICU, those who are mechanically ventilated and even with pneumonia or ARDS (Olsen et al. 2020). As shown in Figure 1, results from the study show that in the light sedation group, the mean RASS score was between -2 and -3 in most patients. An important thing to note is that in these ICUs in Scandinavia mostly, the patient to nurse ratio was 1:1, meaning that the nurses were readily available to make sure that the patient wouldn't self-extubate or be at risk of severe agitation.



Which Drugs Should Be Used?

Guidelines recommend that benzodiazepines should not be used because the use of other drugs is associated with a shorter duration of mechanical ventilation, shorter duration of ICU stay, and less delirium. Benzodiazepines also have one major side effect - more self-extubation.


ARDS is one of the few indications of deep sedation. Deep sedation can be defined by a RASS score between -4 to -5 (Devlin et al. 2018). Some of these patients may need neuromuscular blocking agents (NMBA) to treat ARDS. Findings from a landmark study published in France ten years ago in the New England Journal of Medicine show that Cisatracurium, which is one of the most commonly used NMBA, is associated with better survival compared to placebo (Papazien et al. 2010). More recently, the ROSE trial published by the PETAL Clinical Trials Network in the U.S. did not produce the same results. Findings from this RCT, which enrolled 1000 patients showed that light sedation could be performed by day one in almost 30% of ARDS patients. However, none of them were COVID-19 patients (Moss et al. 2019).


With respect to the use of NMBAs in ARDS, the guidelines and recent reviews based on the RCTs suggest that NMBAs should be avoided in ARDS unless there is:

• Moderate to severe ARDS with a P/F ratio < 150 AND

• Severe dyssynchronies despite deep sedation OR

• High level of inspiratory efforts or respiratory drive

• NMBAs should be reassessed within 24 hours


Another important review published and coordinated by Chanques et al. (2020) summarises how sedation and NMBAs should be used in ARDS patients. According to this review, protective ventilation is the key in ARDS, but if protective ventilation is obtained, it is important to first target mild sedation with almost awake patients using small doses of propofol with or without dexmedetomidine. Moderate sedation should be used if mild sedation is not tolerated by increasing the dose of propofol and dexmedetomidine. Deep sedation should remain at the end of the checklist if the patient is not fully synchronised to the ventilator. Propofol should be used as the first-line drug and then other agents. It is important to keep in mind that some of these patients may need NMBAs even if they are deeply sedated.


Is There a Difference Between COVID-19 Patients and Routine ARDS Patients?

The answer to this question is both yes and no. Yes, because there have been many patients admitted to the ICU for respiratory failure related to COVID-19 disease, generating a very high health care workers workload. Because ARDS is a very classic indication of deep sedation, and in some of these patients, light sedation is not associated with protective ventilation, many of these patients would require deep sedation.


That is why during the pandemic, there have been many deeply sedated patients in ICUs. Also, COVID-19 is a droplet and airborne transmitted disease. Since there have been many patients admitted to the ICU for respiratory failure, generating a very high workload for healthcare workers, and requiring them to wear personal protective equipment, there is a temptation for deeply sedating patients to decrease the risk of incidents such as self-extubation. Because of this high use of sedation during these times and the high flow of patients in severely affected regions, there is a risk of a shortage of deep sedation drugs.


Over the last few months, there have been many reviews and expert opinions, but no comparative studies have been conducted that show that one of these drugs (benzodiazepines, dexmedetomidine, ketamine, volatile sedation, non-opioid analgesics, morphine and other opioids) would be better than the other in COVID-19 patients. Hence, for most clinicians, the strategy has been to follow local policy as well as make decisions based on the availability of drugs. Some of these drugs, such as volatile sedation, are under investigation in ARDS. There is an ongoing RCT in France where intravenous sedation drugs are compared to volatile sedation to see whether volatile sedation would be associated with better outcomes (Ammar et al. 2021; Adams et al. 2020).


COVID-19 and the Brain

One particularity of the COVID-19 disease is that the hippocampus is one of the targets of the virus generating a local inflammatory brain response. There is also a possible brain invasion of the virus through olfactory nerves and systemic acute brain injury related to hypoxia, inflammation, and endothelialitis.


All these pathophysiological pathways lead to cognitive impairment and a high risk of ICU-associated delirium. Recovery times are not yet known, but may be prolonged. No study so far has reported the need for higher doses of sedative drugs in ARDS patients with or without COVID-19 disease.


In conclusion, severe COVID-19 patients may need deep sedation and NMBAs but the goal should always be to target light sedation once we make sure that mechanical ventilation is lung and muscle protective. 


Key Points

  • Mechanically ventilated patients should not be deeply sedated without a specific indication and without daily attempts to lighten sedation.
  • Light sedation is associated with a shorter duration of invasive mechanical ventilation and reduced tracheotomy rates.
  • ARDS is one of the few indications of deep sedation and some patients may require NMBAs to treat ARDS.
  • Protective ventilation is the key in ARDS; if not obtained, the first target should be mild sedation.
  • Moderate sedation should be used only if mild sedation is not tolerated. Deep sedation should remain at the end of the checklist.


«« Cardiac Arrest in COVID-19 - Characteristics and Outcomes


RECOVERY Trial: Tocilizumab in Hospitalised COVID-19 Patients »»

References:

Adams C et al. (2020). Analgesia and Sedation Strategies in Mechanically Ventilated Adults with COVID-19 COVID-19 Analgesia & Sedation Strategies. Pharmacotherapy, 40

Ammar MA et al. (2021) Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages. J Intensive Care Med., 36(2):157-174.

Chanques G et al. (2020) Analgesia and sedation in patients with ARDS. Intensive Care Med.,46(12):2342-2356

Devlin JW et al. (2018) Methodologic Innovation in Creating Clinical Practice Guidelines: Insights From the 2018 Society of Critical Care Medicine Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption Guideline Effort. Crit Care Med.,46(9):1457-1463. 

Halpern SD et al. (2014) Choosing Wisely Taskforce; American Thoracic Society; American Association of Critical-Care Nurses; Society of Critical Care Medicine. An official American Thoracic

Society/American Association of Critical-Care Nurses/American College of Chest Physicians/Society of Critical Care Medicine policy statement: the Choosing Wisely® Top 5 list in Critical Care Medicine. Am J Respir Crit Care Med.,190(7):818-26. doi:

Kress JP et al. (2000) Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med.,18;342(20):1471-7. 

National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M et al. (2019) Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med., 23;380(21):1997-2008.

Olsen HT et al. (2020) Nonsedation or Light Sedation in Critically Ill, Mechanically Ventilated Patients. N Engl J Med.,19;382(12):1103-1111.

Papazian L et al. (2010) ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med.,16;363(12):1107-16.

Shehabi Y et al. (2012) Bailey Sedation Practice in Intensive Care Evaluation (SPICE) Study Investigators; ANZICS Clinical Trials Group. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med.,15;186(8):724-31.



Related Articles

MAY 5-7   EuroELSO 2021 Virtual event https://iii.hm/18rs 31 MAY – 4 JUN  Blood Diseases... Read more

H ealthcare workers across the world have been facing significant challenges due to the COVID-19 pandemic. In particular,... Read more

During the first year, the ICU director should take a snapshot of the ICU situation and invest time and resources to acquire... Read more

Related IssueArticles

This paper describes the experiences of the Speech and Language Therapy (SLT) service at Nightingale Hospital, adapting to... Read more

Perioperative cardiorespiratory compromise is common and goes largely undetected. Predictive cardiorespiratory indices can... Read more

Why digitalisation of intensive care medicine means less rather than more data Intensive Care Medicine is generating... Read more

Pain, sedation, Analgesia, ARDS, COVID-19, critically ill coronavirus patients, COVID-19 ARDS How Should We Manage Sedation in Critically-Ill COVID-19 Patients?

No comment


Please login to leave a comment...

Highlighted Products